Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma
Cancers · 30.04.2023 · 15 (9) · 2584
DOI: 10.3390/cancers15092584 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.04.2023. Verfasst von Maciej Słodkowski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Gastroenterologic and Oncologic Surgery, Medical University of Warsaw, 02-097 Warsaw, Poland. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radical resection is the only curative treatment for pancreatic cancer. However, only up to 20% of patients are considered eligible for surgical resection at the time of diagnosis. Although upfront surgery followed by adjuvant chemotherapy has become the gold standard of treatment for resectable pancreatic cancer there are numerous ongoing trials aiming to compare the clinical outcomes of various surgical strategies (e.g., upfront surgery or neoadjuvant treatment with subsequent resection). Neoadjuvant treatment followed by surgery is considered the best approach in borderline resectable pancreatic tumors. Individuals with locally advanced disease are now candidates for palliative chemo- or chemoradiotherapy; however, some patients may become eligible for resection during the course of such treatment. When metastases are found, the cancer is qualified as unresectable. It is possible to perform radical pancreatic resection with metastasectomy in selected cases of oligometastatic disease. The role of multi-visceral resection, which involves reconstruction of major mesenteric veins, is well known. Nonetheless, there are some controversies in terms of arterial resection and reconstruction. Researchers are also trying to introduce personalized treatments. The careful, preliminary selection of patients eligible for surgery and other therapies should be based on tumor biology, among other factors. Such selection may play a key role in improving survival rates in patients with pancreatic cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General, Gastroenterologic and Oncologic Surgery, Medical University of Warsaw, 02-097 Warsaw, Poland.
- Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, 05-552 Jastrzębiec, Poland.
- Department of Oncology, Medical University of Warsaw, 02-097 Warsaw, Poland.
ORCID-Profile: Leszek Kraj
Zitieren
APA
Słodkowski, M., Wroński, M., Karkocha, D., Kraj, L., Śmigielska, K., & Jachnis, A. (2023). Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma. Cancers, 15(9), 2584. https://doi.org/10.3390/cancers15092584
Vancouver
Słodkowski M, Wroński M, Karkocha D, Kraj L, Śmigielska K, Jachnis A. Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma. Cancers. 2023;15(9):2584. doi:10.3390/cancers15092584
BibTeX
@article{Sodkowski2023,
author = {Słodkowski, Maciej and Wroński, Marek and Karkocha, Dominika and Kraj, Leszek and Śmigielska, Kaja and Jachnis, Aneta},
title = {Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma},
journal = {Cancers},
year = {2023},
volume = {15},
number = {9},
pages = {2584},
doi = {10.3390/cancers15092584}
}
EUVIMED